MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Suletud

SektorTervishoid

14.99 5.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.15

Max

14.99

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+63.54% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.38%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	11M 262M
Eelmine avamishind	9.94
Eelmine sulgemishind	14.99

Uudiste sentiment

By Acuity

50%

135 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. apr 2026, 23:48 UTC

Uudisväärsed sündmused

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19. apr 2026, 23:36 UTC

Uudisväärsed sündmused

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19. apr 2026, 22:47 UTC

Uudisväärsed sündmused

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19. apr 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19. apr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19. apr 2026, 23:38 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19. apr 2026, 23:12 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19. apr 2026, 23:10 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19. apr 2026, 23:09 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19. apr 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18. apr 2026, 01:00 UTC

Uudisväärsed sündmused

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

63.54% tõus

12 kuu keskmine prognoos

Keskmine 23.5 USD 63.54%

Kõrge 31 USD

Madal 16 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

135 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.